<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347929</url>
  </required_header>
  <id_info>
    <org_study_id>SO-2017-1</org_study_id>
    <secondary_id>2014-003623-21</secondary_id>
    <nct_id>NCT03347929</nct_id>
  </id_info>
  <brief_title>NSAIDs in Sciatica NSAIDS IN SCIATICA</brief_title>
  <acronym>NIS</acronym>
  <official_title>NSAIDs in Sciatica (NIS), an Investigator Initiated Randomised Placebo Controlled Trial of Naproxen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ostfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Telemark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ostfold Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether treatment with Naproxen 500 mg twice daily is superior to&#xD;
      placebo for the improvement of leg pain in patients with sciatica. Half of patients will&#xD;
      receive Naproxen while the other half will receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sciatica is an established term for pain radiating from the lower back or buttock into the&#xD;
      leg, commonly caused by a disc herniation. Given their analgesic and anti-inflammatory&#xD;
      mechanisms of action, NSAIDs (Non-steroidal anti-inflammatory drugs) have been, and are still&#xD;
      being regarded as standard therapy for sciatica.&#xD;
&#xD;
      However, very few randomised controlled trials of NSAIDs have been undertaken in sciatica,&#xD;
      and no study has showed clinically meaningful effects as compared to placebo.&#xD;
&#xD;
      Since NSAIDs involve the risk of serious gastrointestinal, vascular and renal side effects&#xD;
      there is a strong need to clarify their potential beneficial effects in sciatica.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leg pain</measure>
    <time_frame>Daily from baseline to day10</time_frame>
    <description>A 0-10 numeric rating scale of average leg pain intensity in the previous 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Back pain</measure>
    <time_frame>Daily from baseline to day10</time_frame>
    <description>24 h average back pain will be assessed by a 0-10 numeric rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>Day 0, day 5, day, day 10, day 12</time_frame>
    <description>Roland Morris Disability Questionnaire modified for use in sciatica</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sciatica symptoms</measure>
    <time_frame>Day 0, day 5, day, day 10, day 12</time_frame>
    <description>Sciatica Bothersomeness Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work</measure>
    <time_frame>Day 0, day 10, day 12</time_frame>
    <description>Ability to work and study as normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement</measure>
    <time_frame>Day 5, day 10</time_frame>
    <description>Global perceived change of sciatica/back problem on a verbal rating scale (Completely gone, much better, better, a little better, no change, a little worse, worse and much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication</measure>
    <time_frame>Daily from day1 to day10</time_frame>
    <description>Intake of Paracetamol 500 mg tablets (rescue medication) for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid medication</measure>
    <time_frame>Daily from day1 to day10</time_frame>
    <description>Intake of opioid medication (weak or strong) for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder</measure>
    <time_frame>Day 5, day 10</time_frame>
    <description>&gt;30% and &gt;50% reduction in leg pain relative to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen 500 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen 500 Mg</intervention_name>
    <description>10 days treatment with Naproxen 500 mg twice daily</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 days treatment with Placebo1 tablet twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Radiating pain below the knee with a severity score of ≥4 on a 0-10 (NRS) in the&#xD;
             previous 24 hours&#xD;
&#xD;
          -  Signs of nerve root/spinal nerve involvement as indicated by at least one of the&#xD;
             following features; myotomal weakness, dermatomal sensory disturbances (e.g. sensory&#xD;
             loss, self-reported tingling/numbness), diminished reflexes, radiating pain&#xD;
             exacerbation by SLR&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Not able to read or speak Norwegian.&#xD;
&#xD;
          -  Unlikely to adhere to treatment and/ or complete follow-up (e.g ongoing serious&#xD;
             psychiatric disease, drug abuse, plans to move)&#xD;
&#xD;
          -  Sciatica of known cause other than disc herniation or degenerative stenosis.&#xD;
&#xD;
          -  Neurogenic claudication, i.e. pain in the legs on walking or standing that resolves&#xD;
             with sitting down or lumbar flexion.&#xD;
&#xD;
          -  Symptoms indicating immediate surgery: cauda equina syndrome or a progressive large&#xD;
             paresis.&#xD;
&#xD;
          -  Women who attempt to conceive, are pregnant or breastfeeding.&#xD;
&#xD;
          -  Previous episodes of asthma, urticaria or allergic-type reactions after taking aspirin&#xD;
             or other NSAIDs.&#xD;
&#xD;
          -  Active or history of peptic ulceration, gastrointestinal bleeding, or perforation.&#xD;
&#xD;
          -  Use of drugs known to increase upper gastrointestinal adverse events in combination&#xD;
             with Naproxen: anticoagulants, aspirin (acetyl salicylic acid), serotonin reuptake&#xD;
             inhibitors and systemic corticosteroids.&#xD;
&#xD;
          -  Hepatic enzyme (ASAT/ALAT) values above 1,5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Renal function tests (creatinin/eGFR) outside normal range&#xD;
&#xD;
          -  Congestive heart failure, established ischaemic heart disease, peripheral arterial&#xD;
             disease, and/or cerebrovascular disease.&#xD;
&#xD;
          -  Known hypersensitivity to Naproxen or any of the excipients (lactose, maize starch,&#xD;
             povidone, sodium starch glycolate, talcum, magnesium stearate, polysorbate 80)&#xD;
&#xD;
          -  Ongoing treatment with aspirin, systemic corticosteroids, diuretics, ACE-inhibitors,&#xD;
             lithium and anticoagulants&#xD;
&#xD;
          -  Scheduled for spinal surgery prior to end of study&#xD;
&#xD;
          -  Reservation against intake of gelatine (the capsules contains gelatine, which among&#xD;
             other things is produced by ingredients from pigs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waleed Ghanima, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ostfold Hospital Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Haugen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ostfold Hospital Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne J Haugen, MD,PhD</last_name>
    <phone>+4791193452</phone>
    <email>annhau@so-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Grøvle, MD,PhD</last_name>
    <phone>+4791814029</phone>
    <email>largro@so-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seksjon for fysikalsk medisin og rehabilitering, Drammen Sykehus, Vestre Viken</name>
      <address>
        <city>Drammen</city>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Froholdt, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Revmatologisk avdeling, Sykehuset Østfold Moss</name>
      <address>
        <city>Moss</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne J Haugen, MD,PhD</last_name>
      <phone>+4791193452</phone>
      <email>annhau@so-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avdeling for fysikalsk medisin og rehabilitering, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens I Brox, MD, PhD</last_name>
      <phone>+4723027441</phone>
      <email>j.i.brox@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fysikalsk medisinsk poliklinikk, Sykehuset Telemark</name>
      <address>
        <city>Porsgrunn</city>
        <zip>3710</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Sætre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avdeling for fysikalsk medisin og rehabilitering, Stavanger Universitetssjukehus</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ståle Mathiassen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

